Wie hoch ist der Preis für EFFECTOR Therapeutics, Inc. (EFTRW)

Preis für EFFECTOR Therapeutics, Inc. (EFTRW) ist $0.0006

Wie hoch ist die Marktkapitalisierung für EFFECTOR Therapeutics, Inc. (EFTRW)

Marktkapitalisierung für EFFECTOR Therapeutics, Inc. (EFTRW) ist $2.82K

EFFECTOR Therapeutics, Inc. (EFTRW) KBV

eFFECTOR Therapeutics, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective translation regulator inhibitors aimed at combating cancer. Their primary investigational drug, Tomivosertib, is an orally administered small-molecule MNK inhibitor currently undergoing Phase 2b clinical trials. This candidate is being evaluated for its efficacy in patients suffering from metastatic non-small cell lung cancer. Additionally, the company is advancing zotatifin, another small molecule engineered to block eukaryotic initiation factor 4A (eIF4E). Zotatifin is presently in Phase 1/2 clinical studies for individuals with various solid tumors. Furthermore, it's being tested in a Phase 2a open-label expansion cohort, in conjunction with fulvestrant and abemaciclib, for patients afflicted with ER-positive breast cancer. eFFECTOR Therapeutics, Inc. also holds a research collaboration and licensing pact with Pfizer Inc., focused on co-developing eIF4E inhibitors. Established in 2012, the company maintains its corporate headquarters in Solana Beach, California.

Jahr	P/B-Verhältnis	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

P/B-Verhältnis

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	P/B-Verhältnis	P/B-Verhältnis-Differenz	Land
Vertex Pharmaceuticals Incorporated VRTX.US	6.2613	-	US
Argenx SE ARGX.US	6.3483	-	NL
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	3.634	-	BE
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR

Unternehmen

P/B-Verhältnis

P/B-Verhältnis-Differenz

Land